This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutInfliximabWhat is infliximabMechanism of actionBiosimilarsApprovalOverviewPosition statementsECCOEULARESPGHANDosing & SwitchingDosingIV dosingAdministration & storageIV administrationStorageSafety informationImportant safety informationSwitchingConsiderations for switchingSafety informationImportant safety informationSafety informationImportant safety informationClinical EvidenceRandomised controlled trial evidenceSummary: randomised controlled trial evidenceSupport & ResourcesMaterials
What is infliximab?Infliximab infusion therapy is an established treatment for many inflammatory diseases1-7Infliximab has more than 20 years of experience as an infusion therapy1

Clinical efficacy of infliximab infusion therapy has been demonstrated across all adult and paediatric indications†1,6,11-15

Appropriate use of infliximab infusion therapy is supported by clinical guidelines in CD/UC, paediatric CD/UC, RA, PsA and AS‡13, 16-22

Evidence from a range of analyses, including randomised controlled trials, registry studies, post-marketing surveillance studies, and retrospective comparisons.Guidelines of the Assessment of Spondyloarthritis International Society (AS), the European Crohn’s and Colitis Organisation (CD, UC), the European League Against Rheumatism (AS, PsA, RA), and the European Society for Paediatric Gastroenterology Hepatology and Nutrition (paediatric CD, paediatric UC).AS, Ankylosing spondylitis; CD, Crohn’s disease; PsA, Psoriatic arthritis; PsO, Psoriasis; RA, Rheumatoid arthritis; TNFi, Tumour necrosis factor inhibitor; UC, Ulcerative colitis.

Please refer to the INFLECTRA® Summary of Product Characteristics for full prescribing information

References:Melsheimer R, et al. Biologics 2019;13:139-78. Danese S, et al. Aliment Pharmacol Ther 2011;33:857-69.Moss AC. Gastroenterol Rep 2015;3(1):63-8. Guariso G, Gasparetto M. World J Gastroenterol 2017;23:5469-85.Aardoom MA, et al. Int J Mol Sci 2019;20:2529. Doi: 10.3390/ijms20102529.Smolen JS, Emery P. Arthritis Res Ther 2011;13(Suppl 1):S2.Remicade™ Summary of Product Characteristics.Medscape. FDA Approvals. September 2005. Available at: https://www.medscape.com/viewarticle/513282. Accessed May 2023. EMA. Remicade™ Scientific Discussion. January 2006. Available at: https://www.ema.europa.eu/en/documents/scientific-discussion-variation/remicade-h-c-240-ii-0065-epar-scientific-discussion-variation_en.pdf. Accessed May 2023.Centocor, Inc. [Public Release: 7 November 2007]. Available at: https://www.fdanews.com/articles/100766-remicade-becomes-first-anti-tnf-biologic-therapy-to-treat-1-million-patients.Dave M, Loftus EV. Gastroenterol Hepatol (N Y) 2012;8(1):29-38.Singh S, et al. Clin Gastroenterol Hepatol 2017;15:1218-25.Gomollon F, et al. J Crohns Colitis 2017;11(1):3-25.Hyams J, et al. Gastroenterology 2007;132(3):863-73.Hyams J, et al. Clin Gastroenterol Hepatol 2012;10(4):391-9.Harbord M, et al. J Crohns Colitis 2017;769-84. [Epub ahead of print].Turner D, et al. jpgN 2018;67:257-91.Turner D, et al. jpgN 2018;67:292-310.Ruemmele FM, et al. J Crohns Colitis 2014;8:1179-207.Smolen JS, et al. Ann Rheum Dis 2020;0:1-15.Gossec L, et al. Ann Rheum Dis 2016;75:499-510.van der Heijde D, et al. Ann Rheum Dis 2017;76:978-91. 
Infliximab
Considerations for switching

Learn about considerations when switching to INFLECTRA®

 Explore Loading

Legal Category: S1A
Further information is available upon request

PP-IFA-IRL-0145 May 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0784. June 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0784. June 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0784. June 2024